FAGR Outperforms Fibrinogen in Predicting Mortality in STEMI Patients: Study Finds
China: A recent study has highlighted the potential role of the fibrinogen-to-albumin-to-globulin ratio (FAGR) as a prognostic marker in patients with ST-elevation myocardial infarction (STEMI) undergoing emergency percutaneous coronary intervention (PCI).
The findings, published in Scientific Reports, indicate that FAGR proved to be a significant predictor of all-cause and cardiovascular mortality in patients with acute STEMI undergoing emergency PCI. A higher FAGR was associated with increased mortality rates, outperforming fibrinogen in prognostic accuracy (ROC curve of 0.720 for all-cause mortality and 0.726 for cardiovascular mortality), highlighting its potential as a valuable prognostic marker in STEMI patients.
STEMI is a life-threatening condition that requires immediate medical intervention to restore blood flow to the heart. Despite advancements in PCI, patient outcomes vary significantly, necessitating the identification of reliable prognostic indicators. The researchers note that while the fibrinogen-to-albumin-to-globulin ratio has been recognized for its association with coronary artery disease (CAD), its role in acute STEMI remains insufficiently explored. To bridge this gap, Lixing Chen, Department of Cardiology, Kunming Medical University First Affiliated Hospital, Kunming, Yunnan Province, China, and colleagues aimed to assess the prognostic potential of FAGR in STEMI patients.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.